18.08
18.08 (0%)
As of Feb 14, 2025
Innoviva, Inc. [INVA]
Source:
Company Overview
Innoviva, Inc. is a company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in other healthcare assets.
| Country | United States |
| Headquarters | burlingame, california |
| Phone Number | 6502389600 |
| Industry | manufacturing |
| CEO | Pavel Raifeld |
| Website | www.inva.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $358.7 |
| Operating Profit | |
| Net Income | $23.4 |
| Net Cash | $111.5 |
Profit Ratios
| Gross Margin | $358.7 |
| Operating Margin | |
| Profit as % of Revenues | 1,533.5% |
| Profit as % of Assets | 1.8% |
| Profit as % of Stockholder Equity | 3.4% |
Management Effectiveness
| Return on Equity | 3.4% |
| Return on Assets | 1.8% |
| Turnover Ratio | 28.2% |
| EBITA | $25.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1,301.1 |
| Total Liabilities | $609.9 |
| Operating Cash Flow | $188.7 |
| Investing Cash Flow | $-63.8 |
| Financing Cash Flow | $-13.5 |
